NCT06153251 2026-03-18
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1 Recruiting
Clinical Trials
41 trialsNCT04504825 2026-03-17
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT04512235 2026-03-17
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT06615479 2026-03-17
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT04923893 2026-03-13
CARTITUDE-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06577025 2026-03-13
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT07149857 2026-03-13
CARTITUDE-10
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06045806 2026-03-05
KarMMa-9
Celgene
Phase 3 Active not recruiting
NCT04674813 2026-02-09
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene
Phase 1 Completed
NCT05182073 2025-12-12
FT576 in Subjects With Multiple Myeloma
Fate Therapeutics
Phase 1 Completed
NCT05722418 2025-09-25
CaMMouflage
Caribou Biosciences, Inc.
Phase 1 Recruiting
NCT06119685 2025-06-03
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
Phase 1/2 Recruiting
NCT03994705 2025-05-15
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Cartesian Therapeutics
Phase 1 Terminated
NCT05347485 2025-04-25
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
Janssen Scientific Affairs, LLC
Phase 2 Completed
NCT01539083 2025-02-04
VCAT
Janssen Scientific Affairs, LLC
Phase 3 Completed
NCT03448978 2024-07-01
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
Cartesian Therapeutics
Phase 1 Terminated
NCT05000450 2024-06-28
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics
Phase 1/2 Terminated
NCT02513186 2024-01-29
Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation
Sanofi
Phase 1 Completed
NCT04025216 2024-01-24
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Gilead Sciences
Phase 1 Terminated
NCT02188368 2023-11-03
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Oncotherapeutics
Phase 2 Terminated
NCT02206425 2023-10-31
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Oncotherapeutics
Phase 1/2 Completed
NCT03318861 2023-10-19
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
Gilead Sciences
Phase 1 Terminated
NCT04171843 2023-09-21
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Precision BioSciences, Inc.
Phase 1 Terminated
NCT04614636 2023-09-21
FT538 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Phase 1 Terminated
NCT04613557 2023-08-31
IMMUNICY-1
Celyad Oncology SA
Phase 1 Active not recruiting
NCT04196491 2023-08-23
KarMMa-4
Celgene
Phase 1 Completed
NCT04093596 2023-08-14
UNIVERSAL
Allogene Therapeutics
Phase 1 Active not recruiting
NCT01881789 2022-11-14
Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma
Amgen
Phase 1/2 Terminated
NCT03168438 2022-01-11
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
GlaxoSmithKline
Phase 1 Terminated
NCT02951819 2021-10-08
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
Janssen Scientific Affairs, LLC
Phase 2 Completed
NCT03943472 2021-08-31
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04626752 2020-11-13
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT02046070 2019-07-17
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
Takeda
Phase 2 Completed
NCT01660750 2017-10-18
11-MM-01
Criterium, Inc.
Phase 1 Completed
NCT01980589 2017-05-30
CHAMPION 2
Amgen
Phase 1 Completed
NCT00908232 2015-01-15
SEQUENTIAL
Janssen-Cilag International NV
Phase 2 Completed
NCT00833560 2014-11-21
A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy
Janssen-Cilag G.m.b.H
Phase 2 Completed
NCT00813150 2014-08-15
Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma
Janssen-Cilag G.m.b.H
Phase 3 Completed
NCT00507442 2013-07-26
EVOLUTION
Millennium Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00531453 2012-01-26
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed